Truitt ML, Ruggero D., New frontiers in translational control of the cancer genome. Nat Rev Cancer. 2016;16:288–304. doi:10.1038/nrc.2016.27
Nedialkova DD, Leidel SA. Optimization of codon translation rates via tRNA modifications maintains proteome integrity. Cell. 2015;161:1–13. doi:10.1016/j.cell.2015.05.022
Ladang A, Rapino F, Heukamp LC, Tharun L, Shostak K, Hermand D, Delaunay S, Klevernic I, Jiang Z, Jacques N, et al. Elp3 drives Wnt-dependent tumor initiation and regeneration in the intestine. J Exp Med. 2015;212:2057–2075. doi:10.1084/jem.20142288
Delaunay S, Rapino F, Tharun L, Zhou Z, Heukamp L, Termathe M, Shostak K, Klevernic I, Florin A, Desmecht H, et al. Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer. J Exp Med. 2016;213:2503–2523. doi:10.1084/jem.20151916
Rapino F, Delaunay S, Zhou Z, Chariot A, Close P. tRNA modification: is cancer having a wobble? Trends Cancer. 2017;3:249–252. doi:10.1016/j.trecan.2017.02.004
Rapino F, Delaunay S, Rambow F, Zhou Z, Tharun L, De Tullio P, Sin O, Shostak K, Schmitz S, Piepers J, et al. Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature. 2018;558:605–609. doi:10.1038/s41586-018-0115-1
Homet B, Ribas A. New drug targets in metastatic melanoma. J Pathol. 2014;232:134–141. doi:10.1002/path.4259
Abildgaard C, Guldberg P. Molecular drivers of cellular metabolic reprogramming in melanoma. Trends Mol Med. 2015;21:164–171. doi:10.1016/j.molmed.2014.12.007
Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 2014;4:423–433. doi:10.1158/2159-8290.CD-13-0646
Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8:705–713. doi:10.1038/nrc2468
